Cytek Biosciences GAAP EPS of -0.05, revenue of 44.9M
CTKB Stock | USD 5.09 0.20 3.78% |
About 66% of Cytek Biosciences' investor base is looking to short. The analysis of overall sentiment of trading Cytek Biosciences stock suggests that many investors are alarmed at this time. The current market sentiment, together with Cytek Biosciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Cytek Biosciences stock news signals to limit their universe of possible portfolio assets.
Cytek |
Cytek Biosciences reports Q1 financial results, with revenue of 44.9M and reaffirms its 2024 revenue guidance of 203M to 213M.
Read at seekingalpha.com
Cytek Biosciences Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Cytek Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Cytek Biosciences Fundamental Analysis
We analyze Cytek Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cytek Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cytek Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Cytek Biosciences is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Cytek Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cytek Biosciences stock to make a market-neutral strategy. Peer analysis of Cytek Biosciences could also be used in its relative valuation, which is a method of valuing Cytek Biosciences by comparing valuation metrics with similar companies.
Peers
Cytek Biosciences Related Equities
APYX | Apyx Medical | 19.27 | ||||
SSKN | STRATA Skin | 2.36 | ||||
LUNG | Pulmonx Corp | 2.14 | ||||
OFIX | Orthofix Medical | 0.99 | ||||
NPCE | Neuropace | 0.95 | ||||
SRDX | SurModics | 0.36 | ||||
LIVN | LivaNova PLC | 0.94 | ||||
ELMD | Electromed | 1.02 | ||||
RXST | Rxsight | 1.10 | ||||
KIDS | Orthopediatrics Corp | 1.61 | ||||
INGN | Inogen | 2.60 | ||||
TMCI | Treace Medical | 2.86 | ||||
SGHT | Sight Sciences | 2.90 | ||||
AXGN | Axogen | 4.02 |
Complementary Tools for Cytek Stock analysis
When running Cytek Biosciences' price analysis, check to measure Cytek Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytek Biosciences is operating at the current time. Most of Cytek Biosciences' value examination focuses on studying past and present price action to predict the probability of Cytek Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytek Biosciences' price. Additionally, you may evaluate how the addition of Cytek Biosciences to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |